Predictive Oncology Inc. (POAI): BCG Matrix [Dec-2025 Updated]

You're looking at Predictive Oncology Inc. (POAI) right now, and honestly, the old playbook is gone. This company is making a massive pivot, ditching its low-revenue biotech roots for a high-risk, high-investment digital asset play, which completely changes how we map its business units using the BCG Matrix. With Q3 2025 revenue barely hitting $3,600 and a huge $343.5 million sunk into new digital assets, the traditional quadrants are radically reshaped; you need to see where their core AI platform lands versus this massive crypto bet.

Background of Predictive Oncology Inc. (POAI)

Predictive Oncology Inc. (POAI) is a knowledge and science-driven company that applies artificial intelligence (AI) and machine learning to support the discovery and development of cancer therapies. The company was incorporated in 2002 and has its headquarters in Pittsburgh, Pennsylvania. Previously, the company was known as Precision Therapeutics Inc. before changing its name in June 2019.

Predictive Oncology Inc. focuses on leveraging its proprietary AI/ML capabilities, an extensive biorepository of tumor samples, and a CLIA laboratory to speed up oncologic drug discovery. The company operates through two main segments: Pittsburgh and Eagan.

The Pittsburgh segment is where the core science happens; it provides services utilizing AI on its proprietary biobank, which holds over 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. A key offering is the validated flagship live cell ChemoFx® drug response assay, which helps oncologists select effective chemotherapies for patients, initially focusing on ovarian and gynecological cancers.

The Eagan segment handles a different area, producing the FDA-cleared STREAMWAY System and related products for automated medical fluid waste management and patient-to-drain medical fluid disposal. In a move to focus on its core AI/ML business, Predictive Oncology Inc. completed the sale of assets related to its former subsidiary, Skyline Medical Inc., to DeRoyal Industries during 2025.

Strategically in 2025, Predictive Oncology Inc. developed a registry using public datasets to identify promising candidates for drug repurposing, flagging three compounds-Afuresertib for breast cancer, and Alisertib and Entinosta for colon cancer-for further exploration. Furthermore, the company initiated a significant digital asset treasury strategy centered on the Aethir (ATH) token.

This digital asset strategy was supported by two private placements that brought in aggregate cash gross proceeds of approximately $50.8 million and in-kind ATH contributions with a notional value of about $292.7 million at signing. As of November 10, 2025, Predictive Oncology Inc. held approximately 5.70 billion ATH, which had a market value of approximately $152.8 million.

Looking at the third quarter of 2025, the company reported continuing operating revenue of just $3,618. Financially, the company ended Q3 2025 with only $181,667 in cash and cash equivalents from continuing operations. The Q3 2025 results also showed a basic and diluted loss per common share from continuing operations of $(107.24), alongside a recorded derivative liability of $74.4 million tied to the ATH treasury strategy.

Predictive Oncology Inc. (POAI) - BCG Matrix: Stars

You're looking at the core engine of Predictive Oncology Inc. (POAI), the proprietary AI/ML platform and its associated biobank. This is where the high-growth potential is anchored, even if current top-line revenue doesn't yet reflect a mature Cash Cow.

The Proprietary AI/ML platform and 150,000+ tumor biobank is the asset base. The platform is named PeDAL™, and it works by screening compounds against more than 150,000 characterized patient tumor samples. This technology is positioned to capture significant value in a market that is expanding rapidly.

The foundational technology underpins high-growth potential, such as drug repurposing. For instance, in the first quarter of 2025, revenue of $110,310 was driven by the completion of a tumor-specific 3D model, a direct output of this core capability. This work has already identified three compounds-Afuresertib, Alisertib, and Entinosta-for further exploration in colon and breast cancer indications.

The market context for this technology is definitely high-growth. The global AI in drug discovery market is projected to reach $1.1 billion this year (2025), with oncology representing a 20% revenue share. Furthermore, the AI-fueled drug pipeline has been expanding at an annual rate of almost 40%.

The strategic vision involves significant capital backing this growth trajectory. The digital asset treasury strategy, focused on the Aethir (ATH) token, brought in aggregate cash gross proceeds of approximately $50.8 million via private placements. As of November 10, 2025, the Company held approximately 5.70 billion ATH tokens, with a market value of approximately $152.8 million based on a price of $0.0268 per ATH. This positions the asset base for high relative market share capture, despite the current revenue scale.

Here's a quick look at the recent financial scale and growth metrics supporting this high-growth positioning:

The high growth rate is evident in the year-over-year comparison, though the absolute revenue remains small relative to the investment required to maintain market leadership in this space. The company is consuming cash to fuel this growth, as seen in the net loss of $77.7 million for the third quarter of 2025, which included a derivative liability of $74.4 million related to the digital asset strategy.

The strategic focus involves leveraging this core technology for future monetization:

• Proprietary AI platform: PeDAL™
• Biobank Size: Over 150,000 tumor samples
• Q1 2025 Revenue Driver: Completion of a tumor-specific 3D model
• Targeted Drug Repurposing Candidates: 3 compounds identified
• Targeted ATH Yield by FY'26: High single-digit

Predictive Oncology Inc. (POAI) - BCG Matrix: Cash Cows

You're analyzing the portfolio of Predictive Oncology Inc. (POAI) and looking for the stable, high-margin businesses that fund everything else. Honestly, based on the latest figures, that quadrant is currently empty for this company.

Predictive Oncology Inc. currently has no established Cash Cow products or segments. A Cash Cow requires a high market share in a mature market, generating more cash than it consumes. The financial data clearly shows that Predictive Oncology Inc. is in a heavy investment and early-stage revenue generation phase, not one of surplus cash generation from established products.

The revenue figures confirm this lack of established, high-volume business units. Total revenue for Q3 2025 was only $3,618. This minimal top-line figure indicates that no segment is generating the significant, stable cash flow characteristic of a Cash Cow. To put this in perspective against an earlier period, the total revenue for Q1 2025 was $110,310.

Furthermore, the company operates at a significant loss, which is the antithesis of a Cash Cow's function. The scenario dictates that the company used $5.9 million in cash for operations in the first nine months of 2025. This cash burn requires funding from external sources or asset sales, rather than being funded by internal product profits. For example, the loss from continuing operations in Q1 2025 was approximately $2.3 million.

All core oncology products are in the Research and Development (R&D) or early commercialization phase, requiring investment, not generating surplus cash. These products are consuming resources to gain market share, positioning them as either Question Marks or potential Stars, but certainly not mature Cash Cows.

Here's a quick look at the financial reality that precludes any segment from being classified as a Cash Cow:

• Q3 2025 Revenue: $3,618
• Q1 2025 Revenue: $110,310
• Cash Used in Operations (9M 2025): $5.9 million (as per scenario)
• Q1 2025 Loss from Continuing Operations: Approximately $2.3 million
• Cash and Equivalents (End of Q3 2025): $181,667

The company's current focus is on building future value, not milking existing assets. The strategic initiatives, such as the digital asset treasury strategy involving ATH tokens, are designed for future monetization, not current cash stability. The ChemoFx® drug response assay, for instance, is noted for its planned European launch and expanded US availability, indicating an early-stage market penetration effort.

You can see the investment profile when looking at the product lifecycle stages:

The company's financial structure reflects this investment need. As of the end of Q3 2025, the stockholders' deficit stood at $77.4 million. This is a clear signal that the business model relies on capital infusion or asset monetization to cover operating expenses, which is the exact opposite of a Cash Cow's role in funding the enterprise.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - BCG Matrix: Dogs

You're looking at the units within Predictive Oncology Inc. (POAI) that are stuck in low-growth markets and have a small piece of that market. These are the classic Dogs-businesses that tie up capital without delivering meaningful returns. Honestly, the strategy here is usually to cut bait, not throw good money after bad.

The move to divest non-core assets clearly signals management's recognition of these low-potential areas. The sale of Skyline Medical assets to DeRoyal Industries in Q1 2025 is the prime example of this strategy in action, designed to sharpen the focus on the higher-potential AI/ML drug discovery platform. This divestiture was a direct attempt to reduce the ongoing expense run rate associated with that business line.

The performance of the legacy product lines strongly supports the Dog categorization. Revenue generated from the tumor-specific 3D models and 3D kits showed a severe contraction in the second quarter of 2025. This segment, which was a source of revenue in prior periods, is clearly declining in relevance or market share.

Here's a quick look at how that specific legacy revenue stream performed:

The Eagan operating segment, which historically produced the STREAMWAY System, appears to be the unit associated with these low-growth, low-return activities. While the search results confirm the sale of the Skyline Medical assets (based in Eagan, Minnesota) in Q1 2025, this action represents a clear strategic move to cut losses from non-performing units, effectively eliminating a major component of that segment.

The overall financial strain reflected by these legacy operations is evident in the latest reported liquidity figures. The company's cash position at the end of the third quarter of 2025 shows the financial drag these units can impose, even as the company tries to pivot.

• Cash and cash equivalents as of September 30, 2025, stood at a critically low $182,000.
• This low balance is a stark contrast to the $612,000 in cash reported at the end of December 2024.
• The Q2 2025 cash position was $506,078, showing significant further depletion by Q3.

Dogs are units where expensive turn-around plans usually don't help, so divestiture is the logical path. The actions taken by Predictive Oncology Inc. align with minimizing exposure to these areas:

• Completed the sale of Skyline Medical assets in Q1 2025.
• Observed a 97.6% quarter-over-quarter revenue decline for the 3D models/kits segment from Q1 to Q2 2025.
• Reported a cash position of only $182,000 as of September 30, 2025.

Finance: draft 13-week cash view by Friday.

Predictive Oncology Inc. (POAI) - BCG Matrix: Question Marks

You're looking at the business units within Predictive Oncology Inc. (POAI) that fit the Question Marks quadrant: high market growth potential but currently holding a low market share. These areas are burning cash now, hoping to become tomorrow's Stars. Honestly, they are a bet on future adoption.

High-Growth, Unproven Ventures

The most significant item consuming cash and representing a high-growth, high-risk proposition is the pivot into digital assets. This is a massive shift outside the core biotech focus.

• Digital Asset Treasury Strategy: A massive investment of approximately $343.5 million in Aethir (ATH) tokens closed on October 7, 2025.
• This strategy is high-risk, high-growth, with an unproven revenue model in the non-core market of decentralized GPU/compute infrastructure.
• The Aethir network spans more than 435,000 GPU containers across 200+ locations in 93 countries.

The Core Business Under Pressure

The traditional oncology business, while holding the core scientific validation, shows minimal current revenue contribution, which is typical for Question Marks that require heavy investment to scale market share.

Here's the quick math on the traditional revenue base:

This minimal revenue suggests the core products are still in the early adoption or scaling phase, fitting the low market share characteristic of this quadrant. The strategy here must be heavy investment to drive adoption quickly, or these units risk becoming Dogs.

ChemoFx® Assay Expansion

The ChemoFx® drug response assay represents a high-potential product in the personalized medicine market, but its current market share is low because expansion is still in the planning and preparation stages. You need to get markets to adopt this tool.

• ChemoFx® is the proprietary live-cell tumor profiling assay for personalized treatment guidance.
• Expansion efforts are focused on the U.S. and a de novo launch in Europe, supported by a $10 million Securities Purchase Agreement announced in July 2025.
• The assay leverages the company's extensive biobank of over 150,000 tumor samples.
• The assay will initially focus on ovarian and other gynecological cancers, with plans to expand to breast, colon, and lung tumor types.

Drug Repurposing Pipeline

The drug repurposing initiative uses the AI platform, PEDAL, to find new uses for shelved drugs. While promising, it is early-stage and requires significant funding to move candidates forward.

The initial screening identified three specific candidates warranting further exploration for new indications:

• Afuresertib (potential for breast cancer indications).
• Alisertib (potential for colon cancer indications).
• Entinosta (potential for colon cancer indications).

The underlying technology, the PEDAL platform, is reported to predict tumor response with 92% accuracy. This technology is the engine, but the pipeline itself is a Question Mark until clinical validation progresses.